Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2024

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI™
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE

Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/
Institute Report
Drug Expenditure Dynamics 1995–2020: Understanding medicine spending in context
Oct 14, 2021
To download files, please accept Functional Cookies. These cookies provide enhanced functionality for a better user experience.

Summary

While the level of drug expenditure is closely watched and often commented upon, the composition of that expenditure and its dynamics are not as well understood. Typically, official statistics of drug spending only include drugs dispensed in pharmacies and do not include drugs used in hospitals, an issue which raises questions about their representativeness of total drug spending.

In this report, for the first time, we have included estimates of total drug spending, including hospitals and net of discounts and rebates. These estimates have been based on official statistics from government agencies in the countries where available, in some cases not previously published internationally.

Key messages in the report:
  • While the level of drug expenditure is closely watched and often commented upon, the composition of that expenditure and its dynamics are not as well understood.
  • The changes in drug spending over the past quarter century have been dramatic in terms of the types of medicine and the diseases they are used to treat.
  • But drug spending as a share of healthcare spending has changed to a lesser degree and has represented greater stability than one might have expected.
  • In every country studied, drug spending is a small proportion of healthcare spending, averaging 15% (and ranging from 9–20%) and has remained relatively flat over the last 20 years, even though the reliance on pharmaceuticals has increased.
  • The cycle of genericization has continued across therapeutic classes, including cancer; and the impact of biosimilars is now also seen.
  • The result of these long-term trends is that medicine utilization has grown over time, driven primarily by increased use of generics.
  • While new medicines are often seen as large drivers of growth, in context each era has different leading classes, and the recent waves of innovation in oncology, diabetes, and immunology mirror the impact of anti-bacterials, cardiovascular and gastrointestinal treatments which drove spending a quarter century ago.
  • As an example, the significant bolus of spending for Hepatitis C from 2013 has largely come and gone, and further illustrates relatively stable long-term trends.

Key Findings

HEALTH AND MEDICINE SPENDING TRENDS

Total drug spending averages 15% of healthcare with countries ranging from 9-20%

  • Drug spending as a percentage of health spending is inclusive of all products and locations where they can be delivered (retail, hospitals) and are reported after discounts and rebates received by payers.
  • Drug spending ranged from 9% in the UK to 20% in South Korea.
  • Most of the major developed countries were between 14–18%, excluding the UK and Canada.

Drug spending has been growing more slowly than health spending in recent periods in most countries

  • When comparing historic growth for drug and healthcare spending, drug spending has been growing more slowly than health spending in most countries, particularly in the last 13 years.
  • Countries where drug spending has been growing faster than healthcare spending consistently include Brazil, Canada, and the UK, which in 2018 still have the three lowest drug spending share of healthcare of the countries studied.
  • Countries with an upward inflection in the most recent period include Spain, the UK, and Germany; however, drug and healthcare spending are still within 1% of each other.

Drug spending share of healthcare has been converging around 15%, where greater variations existed previously

  • Countries’ drug spending share of healthcare has been converging, with countries ranging from 4–28% in 2008 and 9–20% in 2018.
  • Those countries with the highest drug share of healthcare uniformly have lower overall health expenditure, such as Italy, Spain and South Korea, which all spend less than $3,000 per capita on healthcare.
  • Across the 11 countries, average drug spending percentage of healthcare rose somewhat steadily in the late 1990s and then stabilized for most of the last 20 years, averaging 15% of healthcare across these countries.

The top 5 therapy areas in 1995 and the top 5 in 2020 changed dramatically over the period

  • Protected brands represent brands that have been in the market for more than 24 months and still hold market exclusivity.
  • While examining only protected and new brands, the top five therapy classes in 2020 (oncology, immunology, anti-diabetics, anti-coagulants, and HIV anti-virals) have grown from 11% of spending in 1995 to 62% in 2020.
  • The top five therapy classes in 1995 (cardiovascular, anti-bacterial, anti-ulcerants, mental health, and cholesterol) represented 53% of spending in 1995, and have collectively dropped to 6% in recent years, due to generalization and limited innovation.

Spending for protected brands has declined as patent expires and shifts to generics have not been offset by innovation

  • Drug classes such as cardiovascular, anti-bacterials and anti-ulcerants have seen limited new medicines introduced and therefore have had a declining share of spending.
  • In cholesterol-reducing drugs, most treatments were introduced in late 1990s and mid-2000s, and have already lost exclusivity, first with simvastatin in 2006 and then atorvastatin in 2011.
  • In the last five years the new brands contribute to a small share of drug expenditure due to the limited uptake of PCSK9 drugs.

YOU MAY ALSO BE INTERESTED IN

Institute Report
Global Medicine Spending and Usage Trends: Outlook to 2025
Institute Report
The Use of Medicines in the U.S.

Spending and Usage Trends and Outlook to 2025
Institute Report
Spotlight on Biosimilars

Optimising the Sustainability of Healthcare Systems

Contact Us